Trending Now
Qualigen Therapeutics (NASDAQ:QLGN) Announce Expansion Of Research Agreement With the University...
Qualigen Therapeutics Inc. (NASDAQ:QLGN) has announced the expansion of its Sponsored Research Agreement with the University of Louisville to advance Qualigen's Aptamer-linked Anti-Nucleolin (ALAN),...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Telesis Bio Partnership with Beckman Coulter: A Potential Game-Changer for Synthetic...
Telesis Bio's (TBIO) recent announcement of a partnership with Beckman Coulter Life Sciences to create efficient and scalable biofoundries for on-premise DNA...
MAKE IT MODERN
LATEST REVIEWS
Stocks Taking Center Stage as Powell iterates possibility of rate hikes...
In a slightly lukewarm day for Wall Street this Wednesday, the S&P 500 remained largely unmoved, as market participants processed the most...
MAKE IT MODERN
PERFORMANCE TRAINING
Mustang Bio Inc. (NASDAQ:MBIO) Enters Agreement With SIRION For LentiBOOST™ Tech And Starts Dosing...
Mustang Bio Inc. (NASDAQ:MBIO) has announced a license agreement with SIRION Biotech GmbH under which Mustang acquired rights to the LentiBOOST™ technology from SIRION....
CytomX Therapeutics Inc (NASDAQ: CTMX) Announces Phase 2 Findings For Praluzatamab Ravtansine in Breast...
CytomX Therapeutics Inc (NASDAQ: CTMX) has announced that its second phase study of praluzatamab rvtansine in individuals with hormone receptor-positive (HR+)/human epidermal growth factor...
The US FDA Accepts Zosano Pharma Corp (NASDAQ:ZSAN)’s NDA For Qtrypta To Treat Migraine
Zosano Pharma Corp (NASDAQ:ZSAN) received the US FDA's approval for NDA submission for its innovative drug – Qtrypta to cure migraine. If its Qtrypa...
Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) Release Q3 2020 Financial and Operational Results As It Considers...
Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) has announced its results and provided a business update for the three months ended September 30, 2020.
PolarisDMD edasalonexent study failed...
The Green Infrastructure Stock Boom Waits Around the Corner (LXU, ECOX, JCI, HON, BIP,...
As fossil fuel prices power higher due to pandemic reopening, Russia’s invasion of Ukraine, and insufficient investment in production capacity over recent...
MAKE IT MODERN
